Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (331-340 of 344) with videos related to

Pageof 35
Sort By:
Cancer Research Communications|March 16, 2023
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune InfiltrationTakao Morinaga, Takashi Inozume, Masahito Kawazu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsJulie R Brahmer, Georgina V Long, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancersGiovanni Fucà, Romain Cohen, Sara Lonardi, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
The New England Journal of Medicine|May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal CancerKohei Shitara, Elena Elimova, Tianshu Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 StudyKohei Shitara, Sylvie Lorenzen, Jin Li, et al.
JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global ExperienceSteven B Maron, Stephanie Moya, Federica Morano, et al.
JCO Precision Oncology|March 30, 2023
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling ProgramYoshiaki Nakamura, Riu Yamashita, Wataru Okamoto, et al.
Nature|July 14, 2025
Microbiota-driven antitumour immunity mediated by dendritic cell migrationNina Yi-Tzu Lin, Shota Fukuoka, Shohei Koyama, et al.
Pageof 35

Showing results (331-340 of 344) with videos related to

Sort By:
Pageof 35
Cancer Research Communications|March 16, 2023
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune InfiltrationTakao Morinaga, Takashi Inozume, Masahito Kawazu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsJulie R Brahmer, Georgina V Long, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancersGiovanni Fucà, Romain Cohen, Sara Lonardi, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
The New England Journal of Medicine|May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal CancerKohei Shitara, Elena Elimova, Tianshu Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 StudyKohei Shitara, Sylvie Lorenzen, Jin Li, et al.
JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global ExperienceSteven B Maron, Stephanie Moya, Federica Morano, et al.
JCO Precision Oncology|March 30, 2023
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling ProgramYoshiaki Nakamura, Riu Yamashita, Wataru Okamoto, et al.
Nature|July 14, 2025
Microbiota-driven antitumour immunity mediated by dendritic cell migrationNina Yi-Tzu Lin, Shota Fukuoka, Shohei Koyama, et al.
Pageof 35